Rel B-modified dendritic cells possess tolerogenic phenotype and functions on lupus splenic lymphocytes in vitro

Immunology

Volumn 149, Issue 1, 2016, Pages 48-61

  Wu, Haijing ^a   Lo, Yi ^a   Chan, Albert ^a   Law, Ka Sin ^a   Mok, Mo Yin ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

dendritic cells; immune tolerance; immunotherapy; systemic lupus erythematosus; transcription factor

Indexed keywords

ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12P70; INTERLEUKIN 17; LENTIVIRUS VECTOR; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR RELB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION; GENE SILENCING; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRAL GENE DELIVERY SYSTEM; WILD TYPE;

EID: 84981736940     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12628     Document Type: Article

References (53)

1. Mok MY, Li WL. Do Asian patients have worse lupus? Lupus 2010; 19:1384–90.
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245–52.
3. Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology 2008; 123:326–38.
4. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002; 99:351–8.
5. Lu L, Thomson AW. Manipulation of dendritic cells for tolerance induction in transplantation and autoimmune disease. Transplantation 2002; 73(Suppl. 1):S19–22.
6. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002; 23:445–9.
7. Morelli AE, Thomson AW. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev 2003; 196:125–46.
8. Carrasco D, Ryseck RP, Bravo R. Expression of relB transcripts during lymphoid organ development: specific expression in dendritic antigen-presenting cells. Development 1993; 118:1221–31.
9. Neumann M, Fries H, Scheicher C, Keikavoussi P, Kolb-Maurer A, Brocker E et al. Differential expression of Rel/NF-κB and octamer factors is a hallmark of the generation and maturation of dendritic cells. Blood 2000; 95:277–85.
10. Zanetti M, Castiglioni P, Schoenberger S, Gerloni M. The role of relB in regulating the adaptive immune response. Ann N Y Acad Sci 2003; 987:249–57.
11. Shih VF, Davis-Turak J, Macal M, Huang JQ, Ponomarenko J, Kearns JD et al. Control of RelB during dendritic cell activation integrates canonical and noncanonical NF-κB pathways. Nat Immunol 2012; 13:1162–70.
12. Burkly L, Hession C, Ogata L, Reilly C, Marconi LA, Olson D et al. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 1995; 373:531–6.
13. Hang LM, Aguado MT, Dixon FJ, Theofilopoulos AN. Induction of severe autoimmune disease in normal mice by simultaneous action of multiple immunostimulators. J Exp Med 1985; 161:423–8.
14. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677–704.
15. Wolfle SJ, Strebovsky J, Bartz H, Sahr A, Arnold C, Kaiser C et al. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol 2011; 41:413–24.
16. Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998; 28:2760–9.
17. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999; 5:919–23.
18. Kalergis AM, Iruretagoyena MI, Barrientos MJ, Gonzalez PA, Herrada AA, Leiva ED et al. Modulation of nuclear factor-κB activity can influence the susceptibility to systemic lupus erythematosus. Immunology 2009; 128(Suppl. 1):e306–14.
19. Ryseck RP, Bull P, Takamiya M, Bours V, Siebenlist U, Dobrzanski P et al. RelB, a new Rel family transcription activator that can interact with p50-NF-κB. Mol Cell Biol 1992; 12:674–84.
20. Ouaaz F, Arron J, Zheng Y, Choi Y, Beg AA. Dendritic cell development and survival require distinct NF-κB subunits. Immunity 2002; 16:257–70.
21. Weih F, Carrasco D, Durham SK, Barton DS, Rizzo CA, Ryseck RP et al. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κB/Rel family. Cell 1995; 80:331–40.
22. Weih F, Warr G, Yang H, Bravo R. Multifocal defects in immune responses in RelB-deficient mice. J Immunol 1997; 158:5211–8.
23. –/– double-knockout mice. J Exp Med 1997; 185:1359–70.
24. + dendritic cells. Immunity 1998; 9:839–47.
25. Huang DB, Vu D, Ghosh G. NF-κB RelB forms an intertwined homodimer. Structure 2005; 13:1365–73.
26. Scherr M, Eder M. Gene silencing by small regulatory RNAs in mammalian cells. Cell Cycle 2007; 6:444–9.
27. Manjunath N, Wu H, Subramanya S, Shankar P. Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev 2009; 61:732–45.
28. Liechtenstein T, Perez-Janices N, Bricogne C, Lanna A, Dufait I, Goyvaerts C et al. Immune modulation by genetic modification of dendritic cells with lentiviral vectors. Virus Res 2013; 176:1–15.
29. Johnson DJ, Ohashi PS. Molecular programming of steady-state dendritic cells: impact on autoimmunity and tumor immune surveillance. Ann N Y Acad Sci 2013; 1284:46–51.
30. Li M, Zhang X, Zheng X, Lian D, Zhang ZX, Ge W et al. Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J Immunol 2007; 178:5480–7.
31. Luo L, Sun Z, Fang Q, Huang S, Bai X, Luo G. Effects of tolerogenic dendritic cells generated by siRNA-mediated RelB silencing on immune defense and surveillance functions of T cells. Cell Immunol 2013; 282:28–37.
32. Xie J, Wang Y, Bao J, Ma Y, Zou Z, Tang Z et al. Immune tolerance induced by RelB short-hairpin RNA interference dendritic cells in liver transplantation. J Surg Res 2013; 180:169–75.
33. Zhang Y, Yang H, Xiao B, Wu M, Zhou W, Li J et al. Dendritic cells transduced with lentiviral-mediated RelB-specific ShRNAs inhibit the development of experimental autoimmune myasthenia gravis. Mol Immunol 2009; 46:657–67.
34. + regulatory T-cell profile. Inflamm Res 2010; 59:197–205.
35. Wu HJ, Lo Y, Luk D, Lau CS, Lu L, Mok MY. Alternatively activated dendritic cells derived from systemic lupus erythematosus patients have tolerogenic phenotype and function. Clin Immunol 2015; 156:43–57.
36. + T cells by alternatively activated dendritic cells. J Leukoc Biol 2008; 84:124–33.
37. Emmer PM, van der Vlag J, Adema GJ, Hilbrands LB. Dendritic cells activated by lipopolysaccharide after dexamethasone treatment induce donor-specific allograft hyporesponsiveness. Transplantation 2006; 81:1451–9.
38. + T cells. Cell Immunol 2012; 273:85–93.
39. Tuettenberg A, Fondel S, Steinbrink K, Enk AH, Jonuleit H. CD40 signalling induces IL-10-producing, tolerogenic dendritic cells. Exp Dermatol 2010; 19:44–53.
40. + tolerogenic dendritic cells. Immunobiology 2011; 216:1117–26.
41. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7:610–21.
42. + T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178:7018–31.
43. + Treg. Eur J Immunol 2010; 40:1022–35.
44. Boks MA, Kager-Groenland JR, Haasjes MS, Zwaginga JJ, van Ham SM, ten Brinke A. IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction–a comparative study of human clinical-applicable DC. Clin Immunol 2012; 142:332–42.
45. Roncarolo MG, Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells? Eur J Immunol 2008; 38:925–7.
46. Martin E, O'Sullivan B, Low P, Thomas R. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 2003; 18:155–67.
47. Caux C, Ait-Yahia S, Chemin K, de Bouteiller O, Dieu-Nosjean MC, Homey B et al. Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol 2000; 22:345–69.
48. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Moreno C, Drexhage HA, Versnel MA. Lack of CCR5 on dendritic cells promotes a proinflammatory environment in submandibular glands of the NOD mouse. J Leukoc Biol 2008; 83:1194–200.
49. Stoop JN, Robinson JH, Hilkens CM. Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models? Ann Rheum Dis 2011; 70:1526–33.
50. Kalantari T, Karimi MH, Ciric B, Yan Y, Rostami A, Kamali-Sarvestani E. Tolerogenic dendritic cells produced by lentiviral-mediated CD40- and interleukin-23p19-specific shRNA can ameliorate experimental autoimmune encephalomyelitis by suppressing T helper type 17 cells. Clin Exp Immunol 2014; 176:180–9.
51. Zandman-Goddard G, Pierangeli SS, Gertel S, Blank M. Tolerogenic dendritic cells specific for β-glycoprotein-I Domain-I, attenuate experimental antiphospholipid syndrome. J Autoimmun 2014; 54:72–80.
52. Llanos C, Mackern-Oberti JP, Vega F, Jacobelli SH, Kalergis AM. Tolerogenic dendritic cells as a therapy for treating lupus. Clin Immunol 2013; 148:237–45.
53. Mok MY. Tolerogenic dendritic cells: role and therapeutic implications in systemic lupus erythematosus. Int J Rheum Dis 2015; 18:250–9.